Achieve is conducting a randomized, single-dose study comparing the efficacy and safety of a combination of acetaminophen and aspirin vs placebo in the acute treatment of migraine headaches.
Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).
Achieve Clinical Research is conducting a randomized clinical study to evaluate the safety, tolerability, and efficacy of a new drug for the treatment of opioid-induced constipation in adults taking opioid therapy for chronic non-cancer pain.
Achieve Clinical is Conducting a Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of a New Drug for the Treatment of Patients with Fibromyalgia.
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE).
This study is a Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of a New Drug in Subjects with Asthma Inadequately Controlled by Corticosteroids.
This trial is a 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naïve subjects with T2DM inadequately controlled on a maximum tolerated dose or maximum dose according to local label of GLP-1 receptor agonist and metformin.
This is a global, multi-center, randomized, placebo-controlled study to evaluate adverse events of special interest in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) treated with a new drug plus standard therapy vs placebo plus standard therapy.
The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo.
The objective of this study is to evaluate the safety and efficacy of a new Rheumatoid Arthritis monotherapy in moderate to severe Rheumatoid Arthritis (RA) subjects.
Satisfied Users & 
Approved Press Releases
